101 related articles for article (PubMed ID: 32542678)
1. Bayesian profiling for cost with zeros to decompose total cost into probability of cost and mean nonzero cost.
Grunwald GK; Arnett JA; Liu W; Ho PM
Biom J; 2020 Nov; 62(7):1631-1649. PubMed ID: 32542678
[TBL] [Abstract][Full Text] [Related]
2. Two-part models for cost with zeros to decompose effects of covariates on probability of cost, mean nonzero cost, and mean total cost.
Liu W; Grunwald GK; Ho PM
Stat Med; 2019 Jul; 38(15):2767-2782. PubMed ID: 30895636
[TBL] [Abstract][Full Text] [Related]
3. A marginalized two-part model for longitudinal semicontinuous data.
Smith VA; Neelon B; Preisser JS; Maciejewski ML
Stat Methods Med Res; 2017 Aug; 26(4):1949-1968. PubMed ID: 26156962
[TBL] [Abstract][Full Text] [Related]
4. 1-year risk-adjusted mortality and costs of percutaneous coronary intervention in the Veterans Health Administration: insights from the VA CART Program.
Ho PM; O'Donnell CI; Bradley SM; Grunwald GK; Helfrich C; Chapko M; Liu CF; Maddox TM; Tsai TT; Jesse RL; Fihn SD; Rumsfeld JS
J Am Coll Cardiol; 2015 Jan; 65(3):236-42. PubMed ID: 25614420
[TBL] [Abstract][Full Text] [Related]
5. Repeated measures with zeros.
Berk KN; Lachenbruch PA
Stat Methods Med Res; 2002 Aug; 11(4):303-16. PubMed ID: 12197298
[TBL] [Abstract][Full Text] [Related]
6. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
Park ES; Symanski E; Han D; Spiegelman C
Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
[TBL] [Abstract][Full Text] [Related]
7. A mixed-effect model for positive responses augmented by zeros.
Rodrigues-Motta M; Galvis Soto DM; Lachos VH; Vilca F; Baltar VT; Junior EV; Fisberg RM; Lobo Marchioni DM
Stat Med; 2015 May; 34(10):1761-78. PubMed ID: 25682753
[TBL] [Abstract][Full Text] [Related]
8. Zero-inflated spatio-temporal models for disease mapping.
Torabi M
Biom J; 2017 May; 59(3):430-444. PubMed ID: 28187237
[TBL] [Abstract][Full Text] [Related]
9. Use of Bayesian Markov Chain Monte Carlo methods to model cost-of-illness data.
Cooper NJ; Sutton AJ; Mugford M; Abrams KR
Med Decis Making; 2003; 23(1):38-53. PubMed ID: 12583454
[TBL] [Abstract][Full Text] [Related]
10. Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritis.
Cooper NJ; Lambert PC; Abrams KR; Sutton AJ
Health Econ; 2007 Jan; 16(1):37-56. PubMed ID: 16981192
[TBL] [Abstract][Full Text] [Related]
11. Bayesian two-part spatial models for semicontinuous data with application to emergency department expenditures.
Neelon B; Zhu L; Neelon SE
Biostatistics; 2015 Jul; 16(3):465-79. PubMed ID: 25649743
[TBL] [Abstract][Full Text] [Related]
12. A probability metric for identifying high-performing facilities: an application for pay-for-performance programs.
Shwartz M; Peköz EA; Burgess JF; Christiansen CL; Rosen AK; Berlowitz D
Med Care; 2014 Dec; 52(12):1030-6. PubMed ID: 25304018
[TBL] [Abstract][Full Text] [Related]
13. More stable estimation of the STARTS model: A Bayesian approach using Markov chain Monte Carlo techniques.
Lüdtke O; Robitzsch A; Wagner J
Psychol Methods; 2018 Sep; 23(3):570-593. PubMed ID: 29172612
[TBL] [Abstract][Full Text] [Related]
14. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
Dodds MG; Vicini P
Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
[TBL] [Abstract][Full Text] [Related]
15. Bayesian inference for prevalence in longitudinal two-phase studies.
Erkanli A; Soyer R; Costello EJ
Biometrics; 1999 Dec; 55(4):1145-50. PubMed ID: 11315060
[TBL] [Abstract][Full Text] [Related]
16. Comparing hierarchical models via the marginalized deviance information criterion.
Quintero A; Lesaffre E
Stat Med; 2018 Jul; 37(16):2440-2454. PubMed ID: 29579777
[TBL] [Abstract][Full Text] [Related]
17. Data cloning: easy maximum likelihood estimation for complex ecological models using Bayesian Markov chain Monte Carlo methods.
Lele SR; Dennis B; Lutscher F
Ecol Lett; 2007 Jul; 10(7):551-63. PubMed ID: 17542934
[TBL] [Abstract][Full Text] [Related]
18. Augmented Beta rectangular regression models: A Bayesian perspective.
Wang J; Luo S
Biom J; 2016 Jan; 58(1):206-21. PubMed ID: 26289406
[TBL] [Abstract][Full Text] [Related]
19. Bayesian models and Markov chain Monte Carlo methods for protein motifs with the secondary characteristics.
Xie J; Kim NK
J Comput Biol; 2005 Sep; 12(7):952-70. PubMed ID: 16201915
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian approach estimating treatment effects on biomarkers containing zeros with detection limits.
Chu H; Nie L; Kensler TW
Stat Med; 2008 Jun; 27(13):2497-508. PubMed ID: 18167630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
